SOX3 and cancer: The serum SOX3 level was also much higher in advanced cancer patients (824.42 ± 39.01 pg/mL, N = 55) than in early cancer patients (573.39 ± 62.61 pg/mL, N = 5) (Figure 4A; P = .039), and IHC study showed that SOX was highly expressed in advanced gastric cancer tissues compared with that in early tumour (Figure 4B).